Bcl Family Set I
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
A DMSO solution containing 25 μl (10 mM) each of the following inhibitors: A8193 ABT-737, A3935 WEHI-539, A4234 TW-37, and A3007 ABT-263 (Navitoclax)
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL (EC50=78.7 nM), Bcl-2 (EC50=30.3 nM) and Bcl-w (EC50=197.8 nM), respectively. There is no inhibition observed against Mcl-1, Bcl-B and Bfl-1.
WEHI-539, has high affinity (subnanomolar) and selectivity for and potently kills cells by selectively antagonizing the prosurvival activity of BCL-XL (IC50 = 1.1 nM).
TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2 (ki=0.29 μM), Bcl-xL (ki=1.11 μM) and Mcl-1 (ki=0.26 μM), respectively.
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM.
 Tahir S K, Yang X, Anderson M G, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737[J]. Cancer research, 2007, 67(3): 1176-1183.
 Lessene G, Czabotar P E, Sleebs B E, et al. Structure-guided design of a selective BCL-XL inhibitor. Nature chemical biology, 2013, 9(6): 390-397.
 Wang Z, Azmi A S, Ahmad A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer research, 2009, 69(7): 2757-2765.
 Mérino D1, Khaw SL, Glaser SP et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.Blood. 2012 Jun 14;119(24):5807-16.